Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | TDO2 | P48775 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3555727 | 0.98 | HPGD (0.97) | HPGDKDM4EALDH1A1LMNAIDO1 | |
| SCHEMBL12596874 | 0.87 | KDM4E (0.77) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL28941241 | 0.86 | KDM4E (0.75) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL30503469 | 0.86 | KDM4E (0.75) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL3555723 | 0.86 | HPGD (0.75) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL2908238 | 0.86 | KDM4E (0.75) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL12392288 | 0.83 | KDM4E (0.71) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL12848655 | 0.83 | ALDH1A1 (0.71) | HPGDKDM4EALDH1A1LMNAIDO1 | |
| SCHEMBL1145054 | 0.83 | HPGD (0.70) | HPGDKDM4EALDH1A1LMNAIDO1 | |
| SCHEMBL7468908 | 0.81 | KDM4E (0.66) | HPGDKDM4EALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080748-A1 | CHITO-OLIGOSACCHARIDE-DUOCARMYCIN CONSTRUCTS | SIGMA-ALDRICH CO. LLC (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-113439084-B | Sesqui-carcinomycin analogue | 奥克兰联合服务有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-1997045411-A9 | ANALOGS OF CC-1065 AND THE DUOCARMYCINS | — | 1998-04-09 | — | — | WO | disclosed |
| WO-1998011101-A2 | CONDENSED N-ACLYINDOLES AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997045411-A1 | ANALOGS OF CC-1065 AND THE DUOCARMYCINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997032850-A1 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-09-12 | — | — | WO | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5629430-A | ANTICARCINOGENIC AGENTS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| WO-1997007101-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
| EP-0680964-A1 | NEW PIRROLO 3,2-e]INDOL DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND APPLICATIONS | UNIVERSIDAD DE SANTIAGO DE COMPOSTELA (ES) | 1995-11-08 | — | — | EP | disclosed |
| EP-0656360-A1 | TRIFLUOROMETHYLPYRROLOINDOLE CARBOXYLIC ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | HPGD 2584/4885KDM4E 3476/4885ALDH1A1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.